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Dear Readers 
The past surreal year of 2020 occupies a different 
significance in the history of the world. So far, we 
all have responded positively. The technology has 
bridged the gap between individuals even as social 
distancing was practiced. During this time our 
LABRAD was digitalized and is now also available 
on AKU website: https://www.aku.edu/mcpk/
pathology/labrad/Pages/from-the-editors-desk.aspx 
The current issue is thematic on ‘Pediatric 
Diagnostics’. A compilation of articles covering the 
various aspects of pediatric disorders with relevant 
investigations are being presented here. We have some 
interesting discussions like diagnostic tools for HIV 
in infants, fecal calprotectin in inflammatory bowel 
disease, pleuropulmonary blastoma a rare tumor of 
infancy, biotinidase deficiency, utility of chromosomal 
microarray, hemoglobin variants analysis and 
intussusception in pediatric patients. 
Pakistan suffers from a high burden of rare diseases 
due to the prevalent practice of consanguineous 
marriages, lack of awareness, and non-availability 
of clinical metabolic services. Early this year, 
Department of Pathology and Laboratory Medicine, 
in collaboration with Pak-IMD-Net and Pakistan 
Society of Chemical Pathologists launched an e-portal 
‘Ek Sath’ to support children/patients with inherited 
metabolic disorders and their families. To visit Ek 
Sath’s website click the link: https://fal.cn/EkSath 
We value your opinion and feedback regarding topic 
selections, educational and resource materials we can 
provide and ideas on how we can better network and 
communicate using LABRAD.
Dr Lena Jafri, 
Editor LABRAD
From the Editor’s Desk
Early and optimal laboratory diagnosis has an 
important role in the mortality and morbidity of HIV 
infected children as early antiretroviral therapeutic 
(ARTs) interventions in less than five years of age 
have shown better life long outcomes. One third 
population in this age bracket lost their battle of 
lives in infancy if do not get ARTs and proper care 
on time. However, the limitations and challenges in 
laboratory diagnosis and confirmation specifically in 
this age group must be kept under consideration while 
confirming the clinical suspicion.  
Proper utility of the following diagnostic tools in 
the first few months of life can be helpful for child’s 
health:
1. Nucleic acid amplification test (NATs):
	 l It is the recommended diagnostic platform in 
  infants and children up till 18 months of age  
  and must be done at 4–6 weeks of age or at 
  the earliest opportunity thereafter for all HIV 
  expose infants
	 l HIV DNA performed on whole blood 
  specimen or Dried Blood Sample (DBS); HIV 
  RNA on plasma or DBS;
	 l Before starting ARTs, a second specimen  
  should be collected to confirm the initial  
  positive virological test result
2. HIV antibody detection: 
	 l Due to transplacental transfer from HIV 
Laboratory Diagnostic Tools for HIV in 
Neonates and Infants
Dr Safia Moin and Dr Mohammad Zeeshan 
Microbiology 
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  confirmed mother, presence of antibodies in 
  new born serum does not confirm the 
  diagnosis and therefore are not recommended 
  up till 18th months of child’s life.
	 l Antibody-negative results may suggest that 
  infants are unexposed and or uninfected, 
  however if the infant is on breastfeeding 
  the risk of acquisition from HIV confirm  
  mother continues throughout the entire 
  breastfeeding period.
	 l HIV-exposed infants who are well, undergo 
  HIV serological testing at around nine months 
  of age (or at the time of the last immunization 
  visit). Those who have reactive serological  
  assays at nine months should have a   
  virological test to identify HIV infection and 
  the need for ART.
	 l Infants with signs or symptoms suggestive of 
  HIV infection undergo HIV serological testing  
  and, if positive (reactive), virological testing. 
3. Ultrasensitive p24 (Up24) antigen:
 l It is detected through ELISA-based 
  technology and was being considered as  
  reliable  tool, however, after the availability of  
  easy and economical NATs and difficulty in  
  procurement of p24 commercially available 
  kit has made this test almost redundant.  
4. Rapid diagnostic test:
 l Antigen/antibody combination immunoassays 
  that detect HIV-1/2 antibodies as well as HIV- 
  1 p24 antigen are not recommended for   
  1diagnosis of HIV infection in infants.
Table 1: Summary of recommended testing approaches and required actions
Category
Well, HIV-exposed infant 
Infant – unknown HIV exposure
 
Well, HIV-exposed infant at 9 
months
Infant or child with signs and 
symptoms suggestive of HIV 
Well or sick child seropositive 
>9 months and < 18 months




Virological testing at 4–6 weeks 
of age 
Maternal HIV serological test or 
infant HIV serological test
HIV serological test (at last




Repeat testing six weeks or more 
after breastfeeding cessation– 
usually initial HIV serological 
testing followed by virological 
testing for HIV-positive child 
and < 18 months of age
Purpose
To diagnose
To identify or confirm HIV 
exposure
To identify infants who have 
persisting HIV antibody or have 
seroreverted
To confirm exposure
To diagnose HIV 
To exclude HIV infection after 
exposure ceases
Action
Start ART if HIV-infected
Need virological test if HIV-
exposed
1. HIV seropositive need 
 virological test and continued  
 follow up
2.  HIV negative, assume 
 uninfected, repeat testing   
 required if still breastfeeding
Perform virological test if 
<18months of age
Reactive– start HIV care and 
ART if under 24 months, or 
based on national start criteria if 
24 months or more
Infected infants and children < 
24 months of age, need to start 
HIV care, including ART
 Recommended Virologic Testing Schedules for Infants Who Were Exposed to HIV and Who Are at Higher Risk of Perinatal HIV Transmission
Higher Risk: Infants born to mothers with HIV who did not receive prenatal care, did not receive antepartum or 
intrapartum ARV drugs, received intrapartum ARV drugs only, who initiated ART late in pregnancy (during the late 
second or third trimester), received a diagnosis of acute HIV infection during pregnancy, or had detectable HIV viral 
loads close to the time of delivery, including those who received combination ARV drugs and did not have sustained viral 
suppression. 
Age at NAT testing  Birth  14-21 days  1-2 months  2-3 monthsa   4-6 months 
aFor higher risk infants additional virologic diagnostic testing is recommended at birth and 2 to 6 weeks after cessation of 
ARV prophylaxis (i.e., at 8-12 weeks of life).
Key: ART = antiretroviral therapy; ARV = antiretroviral; NAT = nucleic acid test
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Introduction
Intussusception is one of the most common causes 
of acute bowel obstruction in pediatric patients. 
It typically occurs between three to 24 months of 
age, with a male: female ration of 2:1. It is due to 
invagination of intussusceptum (proximal bowel 
segment) into intussuscepiens (more distal bowel 
segment). Hypertrophy of lymphoid tissue in the 
wall of the small bowel plays an important role in the 
development of intussusception. In five to ten percent 
of cases, pathological lead points are identified and 
include polyps, Meckel’s diverticulum, duplication 
cyst etc. The classical symptoms of intussusception 
include abdominal pain, vomiting, and bloody (red 
currant jelly) stools. However, this triad of symptoms 
is seen in less than 25 percent of cases, and other 
clinical features include a palpable abdominal lump in 
the right upper quadrant associated with emptiness of 
the right iliac fossa.
Diagnosis
Intussusception, if not diagnosed early, may lead to 
compromised blood supply to the bowel, which can 
result in bowel infarction, perforation, peritonitis and 
even death. Hence, prompt diagnosis is warranted 
to avoid these grave consequences. The diagnostic 
imaging approach includes x ray abdomen and 
ultrasound for exclusion of other causes of obstruction 
and for confirmation of intussusception. Although 
x ray abdomen has low sensitivity for detection of 
intussusception, i.e., around 45 percent, it helps excludes 
the presence of perforation and pneumoperitoneum. The 
imaging features seen on an abdominal radiograph are 
an elongated soft tissue density mostly in the right side 
of abdomen, with signs of bowel obstruction proximally, 
and paucity of gas distally (Figure 1).
Intussusception in Pediatric Patients: Role of 
Radiology in Diagnosis and Management  
Dr Shaista Afzal and Dr Amna A. Saeed
Radiology and BBS Department 
Low Risk: Infants born to mothers with HIV who received standard ART during pregnancy and who had 
sustained viral suppression (usually defined as confirmed HIV RNA level below the lower limits of detection of 
an ultrasensitive assay) with no concerns related to maternal adherence. 
Age at NAT testing   14-21 days  1-2 monthsa   4-6 months 
aTest may be timed to occur at least 2 weeks after cessation of ARV prophylaxis
Key: ART = antiretroviral therapy; ARV = antiretroviral; NAT = nucleic acid test
Recommended Virologic Testing Schedules for Infants Who Were Exposed to HIV and Who Are at Low Risk of Perinatal HIV Transmission
Figure 1: Soft tissue mass in lower abdomen suggesting colocolic 
intussusception 
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The reported accuracy of ultrasound in diagnosis of 
intussusception approaches 100 percent. The classical 
ultrasound features of intussusception include 
target/crescent in donut appearance in transverse 
section, and pseudo kidney/ sandwich appearance 
in longitudinal section (Figure 2). Ultrasound also 
helps in evaluation of its reducibility (Figure 3). The 
features associated with reduced success rates of 
air enema includes small bowel obstruction, more 
distil location, trapped inter bowel loops fluid and 
lack of Doppler flow in the bowel wall. However, the 
presence of lymph nodes within the intussusception or 
ascites has not been reported to affect the outcome of 
this procedure.
Management
Once diagnosed on imaging, the next step towards 
patient’s management is the use of enema as the first 
line treatment. The technique is to instill air, saline or 
contrast through rectum into the colon under real time 
imaging. The pressure builds up as a result thus helps 
to reduce the intussusception.    
The success rates of air enema reduction and 
hydrostatic reduction under ultrasound guidance 
are almost similar however, the advantage under 
ultrasound guidance is avoidance of ionizing 
radiations. These two techniques are associated with 
low incidence of perforation. Barium enema reduction 
of intussusception may result in peritoneal spillage 
and chemical peritonitis in case of perforation and 
has thus become less popular. Prior to image guided 
reduction, surgical consultation is essential to exclude 
the presence of complications including peritonitis, 
shock, and pneumoperitoneum, as the procedure is 
contraindicated in such conditions.   
During the procedure of hydrostatic enema, 
saline solution is slowly introduced by gravity 
into the rectum through a rectal tube that is 
firmly taped in place. The fluid column is 
maintained at a height of three feet above the 
patient. It is recommended to sustain pressure 
for not more than three minutes in case of 
a non-moving intussusception, and attempt 
the process not more than three times. The 
pressure thus achieved forces retrograde 
movement of bowel through the ileocecal 
valve. 
The method of air reduction involves 
introduction of air through a rectal catheter 
(Figure 4). The 
pressure within the 
colon should not 
exceed 120 mm Hg. 
With the reduction 
of intussusception 
(Figure 5), the 
intracolic pressure 
falls, and hence, 
the presence of 
pressure gauge and 
pop off mechanism 
is very helpful. 
The reported success rate 
of air enema reduction of 
intussusception varies from 
51Percent to 95percent. 
Figure 5: Soft tissue due to 
intussusception in the region 
Figure 3: The ultrasound features seen with successful reduction of intussusception i.e., 
no trapped inter bowel loops fluid and normal Doppler flow in bowel wall.
Figure 2: Ultrasound right upper abdomen shows target/ crescent in donut appearance 
in transverse section and pseudo kidney/ sandwich appearance in longitudinal section, 
consistent with intussusception
Figure 4: Instrument for Pneumatic reduction of intussusception 
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of cecum (a), which started reducing with pneumatic 
reduction. Complete reduction of intussusception was 
achieved and free reflux of air is seen into the small 
bowel loops (b).
In those patients with partial reduction of 
Figure 5: Soft tissue due to intussusception in the region of cecum (a), which started reducing 
with pneumatic reduction. Complete reduction of intussusception was achieved and free 
reflux of air is seen into the small bowel loops (b).
intussusception at first attempt, a 
repeat enema has been reported to be 
successful in around 50 percent of cases. 
The suggested time interval between 
these repeated enemas is from 30 to 60 
minutes.
Recurrent intussusception after image 
guided reduction ranges from five percent 
to 20 percent and half of these occur 
within 48 hours. These show a higher 
incidence of pathological lead points. 
Recurrent intussusception can be managed 
non-operatively and does not necessarily 
warrant surgery, even if it occurs a number 
of times.
Conclusion
It is important to recognize the imaging features of 
intussusception for early diagnosis and to be aware 
of its possible radiological management options for 
prompt treatment and hence to reduce morbidity and 
mortality.
Calprotectin (CP) is a zinc- and calcium-binding 
protein of the S100 family expressed mainly by the 
cytoplasm of neutrophils. It participates in leukocyte 
interactions with the endothelium, cellular adhesions 
leading to the recruitment of leukocytes to inflamed 
intestinal tissue, and with the inflammatory and 
thrombogenic response of endothelial cells.
Calprotectin is recommended for the diagnosis, 
assessment of relapses, follow up and response 
to treatment in inflammatory conditions, such as 
inflammatory bowel disease (IBD), celiac disease, 
necrotizing enterocolitis, acute appendicitis, intestinal 
cystic fibrosis etc. the fecal CP remains stable for up 
to one week when stored at room temperature, thus it 
can be used as an accurate marker for inflammatory 
disorders of gut, especially IBD and it is now a 
recommended biomarker for optimizing management 
of IBD patients. Its concentration is elevated in both 
Crohn’s disease and ulcerative colitis, while treatment 
leads to a decrease in CP concentrations parallel to 
clinical improvement, reflecting mucosal healing. 
In Aga Khan Hospital fecal CP test is performed and 
is intended for use in the quantitative determination 
of human CP levels in stool samples with reference 
range of  <43.2ug/G. It is a good potential marker for 
diagnosis and prognosis of IBD patients. However, 
caution should be practiced while interpreting its 
results, as its levels can also be elevated in other 
inflammatory diseases, infectious diseases of gut and 
even in some neoplastic pediatric tumors.
Fecal Calprotectin as an Inflammatory Marker 
in Inflammatory Bowel Disease
Ms Iffat Arman
Clinical Chemistry
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Diarrheal diseases in children, acute or chronic, 
can have serious long term implications and health 
sequels. It contributes considerably in disease 
burden of low and middle income countries. The 
spectrum of causative agents is extensive depending 
upon nutritional status, socioeconomic condition, 
underlying comorbidities and the geographic domain. 
The paradigm shift in laboratory diagnostic methods 
has proven the improved disease outcome. However, 
conventional methods are still being used as front line 
modalities in resource limited health care settings. 
1. Stool Microscopy 
 a. Direct and concentration methods:
Direct microscopy is one of the oldest 
laboratory diagnostic procedure but still 
equally useful and cost effective for 
identification of enteric ova and parasites. It 
depends upon the microscopist skills; further, 
the conventional concentration methods are 
laborious and messy. Therefore, for improving 
the yield and reducing the cumbersome 
process, the utility of concentration tube with 
build-in Millipore filter has been introduced 
(Figure 1). 
  (a) Unassembled flat-bottomed    
   mixing chamber and filter attached to 
   the conical sedimentation with an 
   inbuilt spoon 
  (b) The sedimentation cone scoop of 
   fecal specimen is assembled to 
   the mixing chamber and then 
   vortexed with the sedimentation cone 
   facing upward
  (c) Tube is then centrifuged after 
   inverting at 400 g for 2 min
  (d) Sedimentation chamber after 
   centrifugation
  (e) Wet mount preparation from the 
   sediment
 b. Trichrome stained fixed smear:
  It is a rapid and simple procedure, which 
  produces uniformly well-stained smears of 
  the intestinal protozoa and differentiate from 
  human cells, yeast, and artifact material on 
  ethanol fixed fecal smears. The main 
  advantage is the visual clarity of the internal 
  structure of ova, cysts and trophozoites of 
  enteric protozoa fresh and polyvinyl alcohol 
  fixed specimen (Figure 2).
Spectrum of Tools for the Detection of Enteric 
Pathogens in A Clinical Laboratory 
Dr Salima Rattani and Dr Mohammad Zeeshan
Microbiology 
Figure 1: Fecal concentration tube and processing
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 c. Modified Acid-Fast fixed smear:
  It is also a simple, rapid and effective staining 
  procedure for the identification of oocysts of 
  coccidian species (cryptosporidium 
  and cyclospora). It can be used on fresh or 
  formalin fixed fecal specimen and duodenal 
  fluid. Immunocompromised population with 
  chronic diarrhea must get evaluated by 
  special request of modified acid-fast stain  
  (Figure 3).
 d. Cellophane (Scotch) tape preparation: 
  This is used to identify the pin worm 
  (Enterobius vermicularis) and their ova 
  around perianal area where female worm  
  lays their eggs at night. Fecal specimen is not 
  appropriate method for identify pin 
  worm. After placing scotch tape on glass 
  slide for microscopic evaluation is performed. 
  For better yield, three consecutive morning 
  sample is recommended (Figure 4).
2. Fecal Culture and Sensitivity 
 It is usually set for isolation and identification 
 of epidemiologically significant enteric bacterial 
 pathogens including Salmonella species, Shigella 
 species, Campylobacter species, Aeromonas 
 species and Vibrio species on fresh fecal or stored 
 and transported fecal specimen in Clary-Blair 
 medium. Rectal swabs can be used in those who  
 has difficulty in specimen collection. Below is the 
 rectal swab collection procedure:
	 m Pass the tip of a sterile swab 
  approximately one in. beyond the anal 
  sphincter.
 m Carefully rotate the swab to sample the 
  anal crypts, and withdraw the swab.
 m Send the swab in Cary-Blair medium or 
  buffered glycerol saline.
Specimen submission during the acute stage of 
infection (usually five to seven days) is essential 
because pathogens decrease in number with time. 
If fresh stool is submitted for culture that is not in 
transport medium, the specimen 
should be transported to 
laboratory and processed within 
two hour after collection. For 
best recovery in cases for delay 
of < 24 hours, refrigerate at 4°C. 
If the initial stool culture is 
negative, then additional fecal 
samples may be submitted for 
testing from different defecations 
on successive days (Figure 5).
Figure 2: Trichrome stain Giardia lamblia (100 X)
Figure 3: Cryptosporidium: Modified acid-fast stain under oil immersion 
(100 X)
Figure 5: Clary-Blair transport medium for fecal specimens
Figure 4: cellophane (scotch) tape collection and preparation method
A B
C D
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3. Enzyme Immunoassays (EIA) 
 This method is helpful for detection of fecal 
 antigen, and toxin. The available tests are for  
 Entamoeba histolytica, Clostridium difficile, 
 Giardia lamblia, Helicobacter pylori, Rotavirus 
 and adenovirus.
4. Multipanel Nucleic acid amplification test  
 (NAT) 
This PCR base technology works on syndromic 
approach and utilize multiple nucleic acid 
sequences or gene targets of diarrhea causing 
agents in a single test run with in span of an hour. 
Therefore, the test is rapid and specific. Below 



















Figure 6: Enzyme-linked immunosorbent assay (ELISA) for detection of virus and/or viral antigen. Left, direct. Right, avidin–biotin.
Bacteria  Virus  Protozoa
n  Clostridium difficile  n  Adenovirus F 40/41  n  Cryptosporidium
n  Shiga-toxigenic E. coli (STEC) 0157  n Astrovirus  n  Cyclospora
n  Shiga-toxigenic E. coli non-O157  n  Norovirus GI/GIl  		 cayetanensis
n  Enterotoxigenic E. coli (ETEC)  n  Rotavirus A  n  Entamoeba histolytica
n  Enteropathogenic E. coli (EPEC)  n  Sapovirus  n  Giardia lamblia
n  Enteroinvasive E. coli (EIEC)/
 Shigella
n  Enteroaggregative E. coli (EAEC)
n  Salmonella
n  Plesiomonas shigelloides
n  Aeromonas
n  Vibrio
n  Vibrio cholerae
n  Campylobacter
n  Yersinia enterocolitica
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PCR I PCR II
The conventional laboratory diagnostic tools for 
gastrointestinal tract infection can be effective 
for parasites, few bacteria and viruses, however, 
the detection ability is dependent strongly upon 
laboratory quality assurance processes and 
competence of technologist. 
For improve patient’s outcomes, it is now 
imperative for health care facilities to be abreast 
with the evolving diagnostic facilities for example 
syndrome based multiplex nested PCR that can 
have long lasting health care impact. 
Pleuropulmonary Blastoma Type III with 
Rhabdomyosarcomatous and Chondrsarcomatous 
Differentiation in a Five year old Child, A Rare Case.
Dr Saman Muhammad Amin and Dr Sabeeh Uddin Siddique
Histopathology
Introduction
Pleuropulmonary Blastoma is a very rare malignant 
tumor of infancy and early childhood arising as 
a cystic and/or solid sarcomatous neoplasm in 
the lung or (rarely) the pleura. This embryonic 
or dysontogenetic neoplasm is the counterpart of 
neuroblastoma, hepatoblastoma, retinonblastoma 
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and Wilms tumor. Pleuropulmonary Blastoma 
tumors are subgrouped as type I (purely cystic), 
type II (solid and cystic) and type III (purely 
solid). 
Case Presentation
A five years old boy presented with mediastinal 
mass. Patient had been initially diagnosed as “Mixed 
germ cell tumor” from outside AKUH and had 
been treated accordingly. We received the specimen 
coded as “Right lung upper lobe and mediastinal 
mass” and it consisted of a single lobe of lung with 
a protruding cystic mass that was already ruptured 
and  a separately lying piece of mass.  The mass had  
lobulated appearance. On sectioning the cut surface 
appeared whitish and glistening. 
Microscopic examination of this mass revealed a 
neoplastic lesion comprising of multicystic structures 
that were lined by respiratory type epithelium and 
underlying  sheets of small primitive malignant 
cells showing a cambium layer like zone. Blastemal  
cells were  present along with sheets of markedly 
pleomorphic cells that showed  abundant eosinophilic 
cytoplasm and relatively eccentrically placed 
hyperchromatic nuclei and variably conspicuous 
nucleoli (Rhabdomyoblastic differentiation) (Figures 1 
and 2). Abundant lobules of neoplastic cartilage were  
also identified that showed  mild to moderate nuclear 
atypia and increased cellularity.  Fascicles of atypical 
spindle shaped cells are also identified. Brisk mitoses 
including atypical mitoses, necrosis (approximately 
20 percent), hemorrhage, fibrosis and dead bone are 
appreciated.  Immunohistochemical stains Desmin 
and Myogenin highlights rhabdomyoblastic cells 
and Cytokeratin AE1/AE3 and TTF-1 highlights 
native respiratory epithelium. The case was  
diagnosed as Pleuropulmonary Blastoma, type III 
(Rhabdomyosarcomatous and chondrosarcomatous 
differentiation).
Conclusion
Pleuropulmonary Blastoma is a rare  tumor and it 
should always be considered in the differentials  
when evaluating small lung biopsies taken 
from children that exhibit cartilaginous and 
mesenchymal components.
Figure 1 Rhabdomyoblastic differentiation.
Figure 2 Pleuropulonary blastoma. Cystic structure lined by epithelium.  
A nodule of cartilage is present in cyst wall along with rhabdomyoblasts.
MAY 2021 VOL 46, ISSUE 3
13
With the ongoing advances in molecular techniques 
new knowledge about molecular mechanisms 
behind etio-pathogenesis of neoplastic processes is 
continuously being acquired. The result is a havoc in 
the fields of pathology and pharmaceutical industry, 
because in addition to the identification of novel 
mutations reclassifying certain tumors as specific 
entities, traditionally being put under umbrella terms 
and waste basket diagnoses, specific therapeutic targets 
are being recognized and drugs are being developed 
by the truck load. Welcome to the era of personalized 
medicine!
The fifth edition of the WHO classification of 
Tumors of Bone and Soft tissue was recently 
published, seven years after the 4th edition. In 
addition to a different and more reader friendly 
pattern of the volume on the whole, a useful addition 
are the headings of Essential and desirable 
diagnostic criteria, Cytological features, revised 
Staging and evidence-based discussion under the 
heading Prognosis and Prediction. Furthermore, 
a number of new and emerging entities have been 
added to this edition, few of which arise mostly 
in the adult population, few solely in the pediatric 
patients and some show overlap and a wide age range 
from infants to the elderly. This article focuses not 
only on the pediatric tumors but those with a wide 
age range have also been discussed as they may 
also be encountered in patients less than 18 years of 
age. Some of these tumors have been established as 
entities while a few are still emerging with ongoing 
clinical, morphological, phenotypic and molecular 
studies. 
Poorly Differentiated Chordoma (PDC)
PDC arises in children, more commonly females, with 
a mean age of 11 years. Axial skeleton, specifically 
skull base is the most commonly involved site. Clinical 
presentation is with headache and symptoms of cranial 
nerve compression. 
Radiology shows origin and destruction of bone, with 
infiltration into the adjacent soft tissue. Heterogeneous 
appearance is seen on CT and MRI.
 
Histologically, the most striking features is absence 
of the physaliphorous cells typical of Chordoma. 
The myxoid background stroma may be only focally 
present. The tumor is composed of epithelioid cells, 
growing in cohesive nests and sheets with abundant 
eosinophilic “pink” cytoplasm. Cytoplasmic vacuoles 
may be seen, imparting signet ring like features. The 
nuclei are pleomorphic, round to oval with vesicular 
chromatin. Numerous mitoses and necrosis are 
generally present (Figure 1).  
Immunohistochemically, positive expression of 
Cytokeratins and Brachyury, but the expression of S100 
is variable. An essential diagnostic feature is the loss 
of nuclear INI-1, which results from deletion of the 
New and Emerging Pediatric Bone and Soft 
Tissue Tumors: An Update from the 5th 
Edition of WHO Blue Book
Dr. Qurratulain Chundriger and Dr. Nasir Ud Din
Histopathology 
Figure 1. H&E stained sections show sheets of epithelioid cells with 
distinct cell borders and cytoplasmic vacuoles.
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SMARCB1 gene. Fluorescent in-situ hybridization is 
the method to evaluate this along with co-deletion of 
EWSR1 locus. This tumor shows worse prognosis as 
compared to Chordoma.
BCOR Family of Tumors
This entity comprises of a group of round cell 
sarcomas, sharing clinical and morphological features 
with other round blue cell soft tissue sarcomas like 
Ewing Sarcoma. Before the identification of BCOR 
gene mutations these tumors were grouped under the 
heading of undifferentiated round cell sarcomas. 
The BCOR gene shows several types of alterations, 
resulting in a group of tumors which either show 
rearrangements and fusion with other genes – BCOR-
CCNB3 most frequently – or have internal tandem 
duplications – BCOR-ITD. The former group belongs 
to patients less than 20 years of age; while, the latter 
along with Primitive Myxoid Mesenchymal Tumor 
of infancy typically arises in infants. Whatever the 
mechanism, the end result is oncogenic activation 
of the BCOR gene along with overexpression, 
identification of which aids in the diagnosis. 
Bones of pelvis, lower extremities and paraspinal 
region are the usual sites of origin for BCOR-CCNB3 
sarcomas. Although they may arise less frequently in 
soft tissue sites as well for example lung, head and neck 
region and kidney. BCOR-ITD and Primitive Myxoid 
Mesenchymal Tumor of infancy mostly occur in soft 
tissues of trunk, retroperitoneum and head and neck 
region. 
Patients present with pain and swelling. Grossly the 
tumor may grow to large sizes of more than 10 cm. 
Microscopically, the distinctive feature in addition to 
the round cell morphology is the presence of a rich 
capillary network, which if growing in kidney, may 
mimic Clear Cell Sarcoma in an infant. The tumor 
cells have finely dispersed chromatin. Some tumors 
may exhibit spindle cell morphology mimicking a 
Synovial Sarcoma and a myxoid background. Strong 
nuclear expression of BCOR on immunohistochemistry 
is the most important marker for diagnosis along with 
expression of SATB2 and Cyclin D1, regardless of the 
mechanism of BCOR gene alteration.
These tumors also sometimes harbor YWHAE-
NUTM2B fusions, as seen in High grade Endometrial 
Stromal Sarcomas and Clear cell Sarcoma of kidney. 
This fusion also results in oncogenic activation of the 
BCOR gene and nuclear BCOR expression. Cyclin 
B3 is additionally expressed by the BCOR-CCNB3 
sarcomas. 
Lung is the most common site for metastatic disease. 
The chemotherapy regimen and five-year survival rates 
for BCOR-CCNB3 sarcomas is similar to that of Ewing 
Sarcoma. Data on other BCOR family sarcomas is still 
not clear.
CIC Sarcomas
These are high grade round cell sarcomas showing 
rearrangements of CIC (Capicua Transcriptional 
repressor) gene, with several fusion partners, DUX4 
being the most common. They were previously 
grouped under the umbrella of undifferentiated round 
cell sarcomas along with BCOR family of tumors and 
represent the most frequent subtype of ‘Ewing-like 
tumors. 
These tumors mostly arise in adolescents with a mean 
age of 25-25 years although a substantial number is 
seen in pediatric patients as well. Deep soft tissues of 
extremities and trunk are the common sites of origin 
with head and neck region being less common, similar 
Figure 2. H&E stained section showed round and spindle cells in a 
BCOR rearranged sarcoma.
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to the BCOR tumor family.  Presentation with mass 
lesion with or without pain is common, as is initial 
presentation with metastatic disease. 
These tumors tend to be large with frequent necrosis 
and hemorrhage. Microscopic examination shows 
lobulated growth with indistinct fibrous stroma. 
Sheets of undifferentiated round cells with admixed 
minor population of epithelioid or spindle cells is 
seen (Figure 3). In contrast to the more common 
Ewing Sarcoma, CIC rearranged sarcomas exhibit 
nuclear pleomorphism with open chromatin and 
variably prominent nucleoli. Mitotic activity is brisk. 
These tumors express CD99 in a patchy distribution 
as compared to diffuse membranous staining seen 
in Ewing Sarcoma. NKX2-2, a marker for Ewing 
Sarcoma, is also negative. WT-1 and ETV4 are also 
expressed consistent and constitute the criteria for 
diagnosis along with molecular evidence of CIC 
mutations. 
CIC-DUX4 fusion is the most common alteration 
seen in more than 95 percent of cases, which results 
from either t(4;19)(q35;q13) or t(10;19)(q26;q13) 
translocations. Other rarer fusion partners include 
FOX04, LEUTX, NUTM1 and NUTM2A. 
Most of these tumors behave aggressively with 
metastatic disease, lung being the most common site. 
The response to Ewing Sarcoma chemotherapy is not 
good and the five-year survival rates are also far worse. 
NTRK-Rearranged Spindle Cell Neoplasm
The WHO defines this group as an emerging group 
of molecularly defined rare soft tissue tumors 
showing a wide spectrum of morphological features 
and coexpressing S100 and CD34. It is a provisional 
category and includes Lipofibromatosis-like neural 
tumors and tumors that closely resemble peripheral 
nerve sheath tumors. Most of these occur in 
patients less than twenty years of age, with the 
latter two seen most in children. They arise in the 
extremities and trunk as either superficial or deep 
tumors. 
Microscopically they exhibit a wide range 
of morphology, at one end of which is 
Lipofibromatosis-like neural tumor and at the other 
end are tumors resembling Malignant Peripheral 
Nerve sheath tumor. The former group shows a 
highly infiltrative pattern of growth comprising 
of spindle cells with bland appearance, having 
indistinct cytoplasm and tapering nuclei. Mild 
nuclear atypia and more cellular examples may be 
sometimes seen. Necrosis is absent and mitosis is 
only scant. The latter group comprises of spindle 
cell tumors exhibiting solid growth, high cellularity 
and prominent stromal bands and perivascular 
keloid like collagen deposition, which is hallmark of 
these tumors. Although the cells are monomorphic, 
the growth pattern with streaming bands and 
patternless areas is typical. A variable mixture of 
these two appearances may also be seen with some 
less cellular areas merging with more cellular foci. 
Some examples may show nuclear pleomorphism 
and high mitotic activity with necrosis. A smaller 
subgroup with NTRK-1 rearrangements shows 
myopericytoma-like morphology. 
S100 and CD34 positivity is the rule, with absent 
SOX10 staining and retained H3K27me3 expression, 
which helps in differentiation from MPNST. Majority 
of them show positive nuclear or cytoplasmic staining 
with anti-Pan-TRK monoclonal antibody, a non-
specific marker for NTRK gene rearrangement. 
Additional testing is required for conclusive diagnosis 
and deciding the appropriate therapy depending on the 
fusion partner. 
Figure 3.  H&E stained sections showing variable appearance of 
epithelioid to round to spindle cells
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Prognosis is grade dependent. The lower grade 
lesions have a propensity for local recurrence 
due to infiltrative growth, while the higher-grade 
lesions exhibit an aggressive course with metastasis 
most commonly to lungs. Targeted therapy against 
receptor tyrosine kinases (TRKs) has a role in the 
treatment of these patients. 
EBV-Associated Smooth Muscle Tumor
This entity arises in the setting of immune 
deficiency in one of three settings in descending 
order: 1- HIV/AIDS 2- after solid organ or 
hematopoietic stem cell transplant and 3- 
congenital or primary immunodeficiency. Children 
are the most affected population in cases of 
primary immunodeficiency, the other scenarios 
being common in adults. The latent period after the 
onset of immunodeficiency is long, spanning up 
to several years. If encountered outside the three 
described scenarios, the patient should be worked 
up for immunodeficiency. 
These tumors can arise at any site in the body 
including solid organs. The most reported in 
CNS (intra and extra-axial). They can reach 
large sizes of more than twenty cm. Cut surface 
is rubbery and firm consistency. Microscopic 
examination shows typical morphology of smooth 
muscle tumors, having interconnected fascicles 
of spindle cells with eosinophilic cytoplasm and 
uniform elongated nuclei. The distinctive features 
of EBV associated tumors is the presence of 
small round primitive appearing smooth muscle 
cells and a variable infiltrate of T lymphocytes 
within the tumor, the latter being more common 
in the setting of HIV infection. Some tumors 
may exhibit hemangiopericytoma-like blood 
vessels. Immunohistochemistry shows positivity 
for Smooth muscle Actin and H-Caldesmon with 
patchy variable Desmin. EBER is consistently 
positive on In-situ hybridization and is required 
for diagnosis. Prognosis is largely dependent 
on the individuals’ overall condition. Most 
of these tumors do not metastasize and some 
have been shown to regress on reduction of 
immunosuppression.
Myxoid Pleomorphic Liposarcoma
It is a highly aggressive and extremely rare 
adipocytic tumor, most commonly occurring in 
children and young adults. It shows features of both 
Myxoid Liposarcoma and Pleomorphic Liposarcoma 
but lacks the genetic alterations of Myxoid 
Liposarcoma, Dedifferentiated Liposarcoma and 
Atypical Lipomatous Tumor. Deep soft tissues of 
mediastinum is the most common site of origin. 
Histologically, these tumors show a mixture 
of appearances with areas having delicate 
curvilinear vascular network, myxoid background 
with lipoblasts and bland primitive round cells 
reminiscent of conventional myxoid liposarcoma. 
There is gradual transition to more cellular 
areas with presence of more pleomorphic 
lipoblasts, necrosis, numerous mitoses and 
severe nuclear atypia. They have a non-specific 
immunophenotype.
Diagnosis requires absence of FUS/EWSR1-
DDIT3 gene fusions of Myxoid Liposarcoma and 
MDM2 amplifications of well-differentiated/
Dedifferentiated Liposarcoma. Myxoid Pleomorphic 
Liposarcoma has aggressive clinical course with 
frequent metastases and poor survival. 
EWSR1-SMAD3-Positive Fibroblastic Tumor
This entity is defined as a benign spindle cell 
tumor occurring in superficial tissues of hands 
and feet. A wide age range is described (one-sixty 
eight years). The tumor is small and painless, 
up to 1-2 cm in size. This tumor is usually well-
circumscribed. Microscopically there is zonation, 
with fascicles of spindle cells growing at the 
periphery of the nodule, while the center is less 
cellular and often hyalinized. The spindle cells 
have a bland appearance and lack significant 
nuclear pleomorphism, mitotic activity or necrosis. 
ERG expression by immunohistochemistry is the 
rule, along with negative SMA and CD34. EWSR1-
SMAD3 fusion is the defining genetic abnormality. 
Complete excision is curative with rare instances of 
local recurrence. 
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A three year old male child presented with headache. 
X-ray was done which showed multiple punched out 
lytic lesions (Figure 1)
A biopsy of skull bone was done which histologically 
showed fragments of bone infiltrated by a neoplastic 
process composed of sheets of ovoid cells with 
nuclear grooves, irregular nuclear membranes and 
eosinophilic cytoplasm. Scattered osteoclast-like giant 
cells were noted. In the background, eosinophils, 
neutrophils and lymphocytes were seen. The 
neoplastic cells were positive for CD1a, S100 and 
CD68. A diagnosis of Langerhans cell histiocytosis 
was rendered after radiology-pathology correlation.
Discussion
 
Langerhans cell histiocytosis (LCH) also known 
as eosinophilic granuloma, is a clonal proliferation 
of Langerhans cells. Langerhans cells regulate the 
immune system and normally found throughout the 
body, especially in the skin, lymph nodes, spleen, lungs, 
liver, and bone marrow. The disease usually diagnosed 
during the first three decades of life. The disease can be 
unifocal or multifocal. It commonly involves skeleton 
(skull>femur>pelvis>ribs).  Monostotic form is more 
common than polyostotic. Skin, lymph node and lung are 
other common sites on involvement. In bone, it comprises 
<1 percent of all bone tumors. Clinical symptoms depend 
on the site involved. Radiographically, in long bones, 
present usually as well-defined lytic lesions, but may have 
ill-defined margins. In skull (50 percent involvement) it 
appears as discretely punched out lesions involving tables 
of skull unevenly resulting in beveled edges. Radiological 
differential diagnosis include osteomyelitis, metastasis, 
primary bone tumor, lymphoma and leukemia. 
 In the affected organs, there infiltration of Langerhans 
cells, accompanied by a variable admixture of 
eosinophils, giant cells, neutrophils, and foamy cells. 
The Langerhans cell express CD1a, CD207 (langerin), 
S100 and CD68 immunohistochemical stains. 
Histologic differential diagnoses include osteomyelitis, 
granulomatous inflammation, chondroblastoma, 
Hodgkin lymphoma and Rosai-Dorfman’s disease. 
LCH is differentiated from osteomyelitis by ovoid cells 
with grooved nuclei and CD1a 
positivity. Chondroblastoma 
contain polygonal cells with 
nuclear grooves and S100 
positive, but negative for CD1a 
and preferentially involves 
epiphysis of long bones. 
Monostotic skeletal 
involvement has excellent 
prognosis. Multifocal disease 
has guarded prognosis.
Radiology Pathology Correlation: Orthopedic 
Pathology
Nasir Ud Din and Dawar Khan
Pathology and Radiology
Figure 1. X-ray head lateral view showing multiple punched out lytic 
lesions, beveled margins and without sclerotic margins.
Figure 2. A) H&E showed sheets of Langerhans cells with scattered osteoclast-like giant cells. B) CD1a 
positivity in Langerhans cells
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Hemoglobin
Hemoglobin (Hb) is an iron binding protein that not 
only transports oxygen but also body’s respiratory 
carbon dioxide. The red colour of cells (hence the 
name) is due to this protein.
There are four subunits of Hb each having one 
polypeptide chain and one heme group. The heme 
group has iron protoporphyrin IX associated with 
a polypeptide chain of 141(α) or 146 (β) amino acid 
residues. The adult Hb has two types of polypeptide 
chains known as alpha and beta chains.  Both 
embryonic and adult Hb have similar alpha chains. 
The other (non-alpha chains) include the beta chain of 
normal adult Hb (α2β2), the gamma chain of fetal Hb 
(α2β2), and the delta chain of HbA2.
Normal hemoglobin types include:
 • Hemoglobin A: 95-98 percent of Hb found in  
  adults comprises of HbA; it’s a combination  
  of two alpha and two beta protein chains.
 • Hemoglobin A2: Adults have only 2-3   
  percent of HbA2 comprising two alpha and  
  two delta protein chains.
 • Hemoglobin F (fetal hemoglobin): It is the  
  major Hb found in fetal stage whereas makes 
  up to 1-2 percent of Hb found in adults. It is 
  composed of two alpha and two gamma 
  protein chains. HbF is replaced by HbA by 
  one-two years of age. 
Mutations in Hb
Hemoglobinopathy is defined as genetic 
defect that results in abnormal structure of 
one of the globin chains of the Hb molecule. 
Hemoglobinopathies are generally single gene 
defects inherited as a dominant trait in majority of 
cases.
As a result of mutations in the globin genes 
there could be either a quantitative reduction in 
production of Hb or a qualitative defect in the 
protein produced. Quantitative defects lead to 
development of thalassemia, whereas qualitative 
defects, also called Hb variants, result in a wide 
range of diseases including sickle cell disease, 
unstable Hb, decreased oxygen affinity, increased 
oxygen affinity and methemoglobinemia. Pakistan 
being a resource constrained country and where 
consanguineous marriages are commonly practiced, 
is a victim to a huge number of patients suffering 
from hemoglobinopathies. This pose a massive health 
problem. In one recent study, the estimated frequency 
reported was 34.2 percent. Another estimate states 
that a total of 5000–9000 children with β-thalassemia 
are born per year, although no documented registry is 
available in Pakistan. An approximate carrier rate is 
five–seven percent, with projected 9.8 million carriers 
in our total population.
Indications for Testing
1. Complete blood count shows RBC indices   
 suggestive of thalassemia trait and/or blood smear  
 shows features of an abnormal hemoglobin.
2. Presenting signs and symptoms in a child 
 suggestive of severe anemia and/or failure to 
 thrive such marked shortness of breath, weakness, 
 lethargy, pale skin, abnormal bossing of facial 
 bones and splenomegaly.
3. Episodes of pain in chest, hands and feet, ulcers 
 formation on bony surfaces (suggesting a specific 
 form of abnormal Hb i.e. sickle cell disease).
4. Family history of hemoglobin disorders; as part of 
 family screening.
5. Prenatal screening in a pregnant female:  
 when either of the parent is high risk or there is 
 a diagnosed/suspected thalassemic child 
High Performance Liquid Chromatography 
for Hemoglobin Variants Analysis in Pediatric 
Population
Dr Natasha Ali, Dr Hajrah Syndeed and Dr Asif Naveed
Haematology
MAY 2021 VOL 46, ISSUE 3
19
 previously born to the couple.
6. As a part of state legislation for neonatal 
 screening programs, where indicated.
Sample
 
Venous sample stored in EDTA tube is required for 
testing. In neonates/infants, a finger stick/heel stick 
(samples taken by pricking the finger or heel of the 
neonate) sample may be collected due to difficult 
phlebotomy and low blood volume in neonates. 
Pretesting special preparation is not required, however 
results of blood transfusion interfere with proper 
interpretation of test. A pre-transfusion sample should 
be preferably sent in cases requiring transfusion.
Principal of High Performance Liquid 
Chromatography (HPLC) 
 
HPLC forms one of important tools for testing for 
hemoglobinopathies. Different types of hemoglobins 
are separated based upon the ionic charges they 
carry. An analytical cation exchange cartridge uses 
a preprogrammed buffer gradient. The hemosylate 
passes through the cartridge and separates hemoglobin 
fractions upon interaction 
with resin. There’s a flow 
cell where absorbance is 
measured at 415 nm and 
again at 690 nm to reduce 
background noise. Separated 
fractions pass through this 
flow cell. Changes produced 
in absorbance due to passage 
of fractions of hemoglobins 
are measured and recorded 
over time producing a 
chromatogram (absorbance 
vs. time). 
Each type of hemoglobin has 
a specific retention time which is characteristic to it, 
hence leading to its identification. This retention time 
is measured from the time of sample is injected into 
the HPLC to the highest point achieved by each peak. 
This peak determines the maximum elution for that 
type. While assessment, there can be other peaks in 
the chromatogram which are labeled as Unknown. 
These peaks are due to hemoglobin fractions that 
elute at a retention time which is not pre-programmed 
according to the dictionary of the instrument. 
HPLC leads to separation as well as quantification of 
HbF and HbA2. It also detects variant hemoglobins 
(sickle cell Hb, Hb C, HbD, HbE) along with 
thalassemia.
HPLC is equally capable for identifying 
hemoglobinopathies from both newborns/pediatric 
and adult populations and takes the benefit of the 
algorithm/software/instrument specification.
Interpretation of Results
The report provides the presence of normal as well as 
vairant hemoglobins in order of their quantification. 
Along with pathologist review, the results are 
interpreted in close relation with patient’s sign and 
symptoms and family history.
The following table provides some examples of test 
interpretation: (This table suggests the role of genetic 
mutation contributing towards the pathogenesis: final 
conclusion requires genetic studies).
Heterozygous: One gene copy for variant Hemoglobin
Homozygous: Two gene copies for variant Hemoglobin
Conclusion
HPLC forms a reliable method for both diagnosis as 
well as screening for suspected hemoglobinopathy in 
pediatric population. It is a simple technique which is 
highly reproducible with automation, high resolution 
and rapid results with a short turnaround time thus 
facilitating patient and physicians. The definitive 
diagnosis may require genetic testing in small fraction 
of patients only.
Results seen
Hb A: 50-65 percent
Hb S: Up to 45 percent
Hb S: More than 80 percent
Hb F: 2-20 percent
Hb A: Absent
Hb C: More than 80 percent
Hb A: Absent
Hb F: More than 80 percent
Hb A: Present in small amount or 
completely absent
Hb A: More than 80 percent
Hb A2: Increased (4-8 percent)
Hb F: Usually increased slightly 










Homozygous for HbS 
Homozygous for HbC 
Both beta genes mutated
Mutations in one beta gene 
leading to decrease production 
from one beta globin chain
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Pediatric medicine has changed a lot since the advent 
of more advanced molecular diagnostic techniques 
and neo-adjuvant therapy. This is particularly true for 
solid pediatric tumors. Talking about renal tumors, in 
contrast to getting a resection specimen for primary 
diagnosis, more and more patients are being first 
treated with neo-adjuvant chemotherapy followed 
by surgical resection. This has resulted in refined 
and revised guidelines for reporting and treatment. 
Wilm’s tumor is one of the most commonly occurring 
malignant pediatric renal tumors in children up to 
six years of age. The most common presentation is a 
mass felt in the abdomen, mostly by the mother. Some 
cases of presenting with tumor rupture have also 
been reported. Radiologically it presents as a solid 
mass in the kidney with sometimes associated foci of 
calcifications. In certain parts of the world including 
south Asia, pre-operative chemotherapy has become 
standard in Wilms tumor patients. 
In this article, we will review the parameters for 
reporting of post chemotherapy nephrectomy 
specimen and their implications in further treatment of 
patients. 
Wilms Tumor 
Nephroblastoma or Wilms tumor is the most commonly 
encountered surgical pathology specimen in the 
histopathology lab with status-post chemotherapy 
resection. The guidelines for reporting the changes 
secondary to chemotherapy have evolved over the 
years. The WHO blue book for renal tumors discusses 
two groups of thoughts in this regard. The two main 
stakeholders are the Children’s’ oncology group 
(COG) and Society of Pediatric Oncology (SIOP). The 
COG advocates initial resection of tumor, followed 
by therapy, based on histological findings of grade 
and stage, while the SIOP applies to resection after 
the administration of neo-adjuvant Chemotherapy. 
Under COG, only special circumstances allow for the 
administration of pre-operative therapy which include 
Congenital solitary kidney, inoperable tumor, bilateral 
tumors, vena caval tumor thrombus above the level of 
hepatic vein, direct extension into adjacent structures 
like pancreas, spleen colon and presence of extensive 
metastases in the lung. 
Post chemotherapy resection provides the advantage of 
tumor shrinkage, less instances of per-operative rupture 
and hence stratification into lower stage group. The 
SIOP guidelines for these specimen help in deciding 
the next step in management. While the COG takes 
into account the tumor biology and chooses the therapy 
regimen and protocol based on the primary appearance 
and histology of the tumor. Both groups have shown 
more or less similar outcomes in terms of disease 
stratification according to stage and overall survival. 
The following table highlights differences in COG and 
SIOP staging systems, as described by the WHO blue 
book (bold text):
Updates in Reporting Wilms Tumor 
(Nephrectomy) Specimen






Tumor limited to kidney (may show minimal infiltration of 
renal sinus soft tissue but without vascular invasion) and 
completely resected
Tumor extends beyond kidney (renal capsule invasion, 
lymphovascular invasion, renal vein invasion with negative 
renal vein margin and renal sinus fat invasion) but is 
completely resected with negative surgical margins
SIOP
Tumor limited to kidney without any infiltration of renal 
sinus soft tissue. Presence of necrotic tumor outside these 
parameters does not upstage it. 
Tumor extends beyond kidney (renal capsule invasion, 
lymphovascular invasion, renal vein invasion with negative 
renal vein margin and renal sinus fat invasion) but is completely 
resected with negative surgical margins
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Post-operative Chemotherapy
These changes in the staging system are significant 
for choosing the next step in patient treatment. Post-
surgical therapy is a routine according to COG except 
in patients who are less than two years at diagnosis, 
favorable tumor histology tumor of less than 550 gms, 
stage I as defined above with negative lymph nodes. 
Similarly, SIOP also recommends post resection 
chemotherapy in all patients except those with Stage I 
disease and low risk tumors. 
Post-operative Radiation
COG: recommends radiating the tumor bed in stage 
III disease.
SIOP: recommends radiating the entire abdomen in 
patients with high risk histology, tumor rupture or 
peritoneal deposits. The importance of favorable or 
unfavorable histology also comes into account when 
decision for including the lungs in radiation field 
needs to be taken.  
Reporting of surgical pathology specimen: 
Gross Observations of Intact Specimen 
The following points are mandatory for synoptic 
reporting of gross (and microscopic) findings: 
 - Intactness of Gerota’s fascia is an important 
  parameter in staging the tumor
 - Status of renal capsule
 - Weight of the specimen
 - Tumor focality
 - Size of the tumor
 - Presence of renal sinus involvement grossly  
  and microscopically
 - Involvement of Renal vein with mention of  
  resection margins 
 - Involvement of adjacent organs if present in  
  the resection specimen
 - Status of resection margins
Following parameters can be assessed exclusively on 
histological examination: 
- Histologic type – define histology (favorable,  
 focal anaplasia, diffuse anaplasia)
- Post-therapy histologic classification
Anaplasia in Wilms Tumor
The WHO defines Anaplasia as “Cells with huge 
hyperchromatic nuclei associated with multipolar 
mitotic figures”. To classify as anaplastic, the largest 
dimension of these nuclei should be more than three 
times the largest dimension of tumor cell nuclei in 
other areas. Atypical mitotic figures are larger than 
normal mitoses and exhibit more than two poles. 
Another term worthy of mentioning is “Severe 
nuclear unrest” which is defined as severe nuclear 
atypia approaching the criteria of anaplasia but not 
meeting the criteria. 
Focal anaplasia is presence of 1 or few sharply 
outlined tiny foci of anaplasia within the intrarenal 
tumor. The remaining tumor must not exhibit severe 
nuclear unrest. 
Diffuse anaplasia is the presence of any amount 
of anaplasia in any of the extrarenal sites i.e. renal 
sinus, lymphatic/vascular channels, extra capsular 
tumor deposits, lymph nodes or other metastatic 
sites. Presence of any anaplasia, albeit a single cell 
or a single atypical mitotic figure in a random biopsy 
qualifies for diffuse anaplasia. 
Post-Therapy Histologic Classification 
Chemotherapy-induced changes include necrosis, 
xanthomatous histiocytic foci, hemosiderin deposits 
and fibrosis. Chemotherapy-induced maturation may 
also be seen in some instances. The most commonly 
seen pattern of differentiation is skeletal muscle. Post-
chemotherapy histologic findings are used to classify 
patients into groups with low, intermediate or high 
Residual tumor (positive margins, rupture, surgical spill, 
positive nodes, piecemeal excision and necrotic tumor or 
chemotherapy-induced changes at resection margins or in 
lymph nodes)
Metastasis (hematogenous or lymph node beyond the renal 
drainage system, i.e. outside abdomino-pelvic region)
Bilateral renal involvement on initial diagnosis (both kidneys to 
be staged separately)
Residual tumor (positive margins, rupture, surgical spill, 
positive nodes, piecemeal excision and pre-operative biopsy)
Metastasis (hematogenous or lymph node beyond the renal 
drainage system, i.e. outside abdomino-pelvic region)
Bilateral renal involvement on initial diagnosis (both kidneys 
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risks of poor survival and aggressive behavior of the 
disease.
The categories outlined by the COG and SIOP apply 
only to Wilms tumor with favorable histology. These 
categories are based on quantifying the proportion 
of viable, blastemal tumor. The staging for post 
therapy nephrectomy specimens differs only in the 
interpretation of areas of necrosis outside the kidney. 
The presence of necrotic tumor or chemotherapy-
induced changes in a lymph node or at the resection 
margins is regarded as proof of previous tumor with 
potential microscopic residual disease, and therefore 
the tumor is assigned stage III. The overall idea is 
tumors with most of the tumor being viable and 
composed of Blastema after chemotherapy is going 
to behave more aggressively. The following table 
explains the risk groups based on the amount of viable 
tumor with the proportion of Blastema. Also refer to 
Figures 1 and 2 for histologic appearance of tumor. 
Risk Stratification Parameters
Low risk No viable tumor. Residual nephrogenic rests may be seen
Intermediate risk Viable tumor, <33 percent of the mass regardless of histology
Viable tumor, >33 percent of the mass, with <66 percent Blastemal histology in viable areas
High risk Viable tumor, >33 percent of the mass, with >66 percent Blastemal histology in viable areas
Reference: https://documents.cap.org/protocols/cp-pediatric-wilms-biopsy-19-4000.pdf
Conclusion
Pediatric renal neoplasms are being studied in 
the context of molecular testing with the aim 
of developing targeted and more sophisticated 
therapeutic options. Our understanding of the 
biological mechanisms underlying pathogenesis 
and potential for aggressive behavior are evolving. 
This area of cell biology and cancer genomics 
is definitely going to see a huge growth in 
the upcoming years, with the advent of newer 
drugs like immunotherapeutic agents recently 
developed for a number of solid tumors. Our 
aim as physicians and health care providers is to 
provide the best therapeutic options catered to 
the individual patients’ needs and reporting of all 
the parameters which will help and guide in this 
regard.
Figure 1 This image shows a few residual tubules surrounded by a zone 
of fibrosis and hemorrhage with scattered inflammatory cells (taken from 
webpathology.com).
Figure 2 Few residual nodules of blastema and scattered tubular 
elements. Post-chemotherapy specimens in which blastemal component 
constitutes more than 2/3 of the viable tumor are considered high risk 
tumors (taken from webpathology.com).
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Biotin, widely known as hair and skin vitamin, is a 
water-soluble vitamin present in small amount in various 
foods. It is recycled in the biotin cycle by the action 
of the enzyme Biotinidase a glycoprotein detectable 
in dried blood spots, serum, leukocytes, fibroblasts, 
and hepatocytes. Biotinidase Deficiency (BD), is an 
inherited autosomal recessive disorder caused by 
absent or markedly deficient activity of the enzyme 
biotinidase. As biotin serves as the cofactor of the four 
human carboxylases, BD results in multiple carboxylase 
deficiency, a potentially life-threatening disorder with 
impairment of gluconeogenesis and organic acids 
metabolism.
The incidence of BD is 1:40,000 to 1:60,000 births in the 
world; however, in countries with higher consanguinity 
rate, such as the United Arab Emirates and Turkey, 
the frequency is significantly higher, 1:8300 and 1:14,800 
respectively. Additionally, the carrier frequency in the general 
population is shown to be approximately one in 120. 
From a clinical perspective, cases with BD present 
with broad spectrum of neurological, dermatological 
and systematic manifestations, ranging from seizures, 
hypotonia, feeding problems, delayed motor and cognitive 
development, ophthalmologic issues, hearing difficulties, 
hair loss, eczematous skin rash and recurrent infections.
BD is included in the Recommended Uniform Screening 
Panel for Newborn screening (NBS) by the Department 
of Health and Human Services, United States of America, 
which traces back to 1985 when a swift colorimetric assay 
for evaluating biotinidase activity on dried blood spots 
was developed. Collection of blood onto an absorbent 
paper card, often referred to as a ‘Guthrie card’, is the 
commonest type of NBS sample as shown in figure 01. 
A few drops of blood from a heel prick are collected 
onto a filter paper and sent to the laboratory for analysis.
In countries, like Pakistan that lack NBS, high risk 
screening of suspected cases of BD is usually built upon 
clinical findings, hyperammonemia, metabolic ketolactic 
acidosis and the presence of 3-hydroxyisovaleric acid, 
lactic acid, 3-hydroxypropionic acid, 3-mehtylcrotonyl 
glycine and methyl citrate in the urine organic acid 
analysis by gas chromatography mass spectrometry. 
For the confirmation of diagnosis quantification of 
biotinidase enzyme activity in serum/plasma is usually 
recommended using tandem mass spectroscopy. Based 
on the results, a diagnosis of profound (less than 10 
percent of the mean normal biotinidase activity) or partial 
(10-30 percent of mean normal biotinidase activity) BD 
is established. Molecular analysis based on identification 
of biallelic pathogenic variants in biotinidase gene is 
considered when the results of enzymatic testing are 
equivocal in differentiating profound from partial BD 
and further evaluation is necessary. 
Cases with BD identified by NBS continue to be 
symptom free and show normal development if biotin 
therapy is introduced promptly and uninterruptedly. 
The simple, relatively inexpensive and widely available 
treatment is usually based on 5-10 mg of oral biotin per 
day. Furthermore, cases with profound and partial BD, 
even diagnosed at later stages due to lack of NBS have 
shown good outcomes and better prognosis on treatment 
with oral biotin. In context of cost effective screening 
tests, availability of confirmatory assays, in expensive 
and widely available treatment, the prognosis of BD is 
better compared to other enzyme defects and organic 
acidemias, provided timely initiation and compliance 
with therapy. The monitoring is done clinically and 
periodic follow-up visits with the metabolic physician 
are needed to ensure that the features of the condition 
have resolved with therapy.
Biotinidase Deficiency- a Rare but Treatable 
Disorder
Dr Sibtain Ahmed 
Chemical Pathology
Figure 1 showing Heel Prick on dried blood spot filter paper for 
DBS-Biotinidase analysis
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Renal tubules play an important role in fluid, electrolyte 
and acid-base homeostasis. Normal reabsorption of 
electrolytes, glucose, calcium, magnesium, phosphates 
and amino acids and secretion of protons occur in 
various specialized parts of the renal tubule. Tubular 
dysfunction should be observed in all children with 
hypokalemia and metabolic acidosis, failure to thrive, 
polyuria, refractory rickets. Common disorders of renal 
tubular dysfunction are shown in Table 1.
Assessment of Renal Tubular Acidosis (RTA)
The clinical features suggestive of renal tubular 
disorders are refractory rickets, unexplained 
hypertension (Liddle’s syndrome), growth retardation, 
failure to thrive, polyuria, polydipsia; preference for 
savory foods, renal calculi, nephrocalcinosis etc. 
On laboratory investigation these patients present 
with hypercalciuria with normal serum calcium, 
hyponatremia with hyperkalaemia, metabolic alkalosis 
with or without hypokalemia and hyperchloremic 
metabolic acidosis. The following laboratory findings 
are helpful in evaluating and classification of RTA.
Plasma anion gap: Anion gap shows the difference of 
unmeasured anions and cations in the plasma, and is 
measured as follows: Anion gap = Na+ – (Cl– + HCO3–). 
Normal plasma anion gap is 10-12 mEq/L. Normal 
anion gap in the presence of acidosis (hyperchloremic 
metabolic acidosis) suggests elevated urinary (proximal 
RTA) or gastrointestinal loss (diarrhea) of bicarbonate 
or impaired excretion of H+ ions (distal RTA).
Urine anion gap: Urine anion gap (net charge) 
(urine Na+ + K+ – Cl–) gives an estimate of urinary 
ammonium (NH4+) excretion and is beneficial 
in the evaluation of hyperchloremic acidosis. 
Under normal circumstances, urine anion gap is 
positive due to the presence of dissolved anions 
e.g., sulfates, phosphates. Metabolic acidosis is 
link with a compensatory rise in NH4+ production, 
resulting in a negative 
urine anion gap. Patients 
with RTA typically 
represents impaired renal 
NH4+ excretion and a 
positive urine anion gap.
Urine pH: Urine pH is 
an estimate of the number 
of free H+ ions in the urine 
which are secreted in 
response to metabolic acidosis. The presence of alkaline 
urine during metabolic acidosis represents defective 
renal acidification, as in distal RTA. However, alkaline 
urine may also be found in patients with metabolic 
acidosis due to extra-renal disorders, as in diarrhea.
Fractional excretion of bicarbonate: The proximal 
tubule normally reabsorbs almost all filtered bicarbonate 
(fractional excretion below five percent). A value more 
than 10 percent indicates proximal RTA while levels 
are in the normal range in distal RTA. Proximal tubular 
handling of bicarbonate can be evaluated by fractional 
excretion of bicarbonate.
Tests for Potassium Handling
Renal tubular disorders may be associated with both 
hypokalemia and hyperkalemia. 
Renal Tubular Disorders and Biochemical 
Diagnostics
Dr Siraj Muneer and Ms Iffat Arman
Clinical Chemistry
Table 1: Common Disorders of Tubular Functions
Segment Function Disorder
Proximal tubule Amino acid transport Aminoaciduria
Bicarbonate transport Proximal RTA
Phosphate transport Hypophosphatemic rickets
Glucose transport Renal glucosuria
Ascending limb of Henle Chloride, potassium, sodium transport Bartter syndrome
Distal tubule Sodium, chloride transport Gitelman syndrome





Water transport Nephrogenic DI
urine bicarbonate x plasma creatinine 
Fractional excretion =  x100
of bicarbonate  plasma bicarbonate x urine creatinine
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The fractional excretion of potassium (FEK) may 
also be used as an indicator of tubular function; 
FEK values <2 indicates extra-renal causes while >2 
indicates renal causes.
We can differentiate patients into three types 
of tubular disorders based on these routine 
biochemical tests, shown in table 2. Identification 
of correct type of disorders is critical to patient 
management. Hence it is imperative that all 
patients suspected of any renal tubular disorder are 
investigated thoroughly and managed accordingly.
  urinary potassium x plasma
   osmolality
Transtubular gradient of potassium = 
  plasma potassium x urinary osmolality


















(Hyperchloremic) Yes Yes Yes Yes Yes
Serum K Normal/Low Normal/Low High Normal/Low High
Urinary Anion Gap Positive Positive Positive Negative Positive
Urine pH >5.5 >5.5 >5.5 <5.5 <5.5
Fractional HCO-
3
 Excretion <5 percent >5-15 percent <5 percent >10-15 percent >5-10 percent
Fractional K+ Excretion High High Low Normal/High Low
NH4+ Excretion Decreased Decreased Decreased Normal Decreased
Calcium Excretion Increased Increased Increased Normal Normal/Decreased
Citrate Excretion Decreased Decreased Decreased Normal Normal
Nephrocalcinosis/Lithiasis Often Present Often Present Often Present Absent Absent
Bone Involvement Rarely Present Rarely Present Rarely Present Often Present Absent
Other Tubular Defects Absent Absent Absent Often Present Absent
Utility and application of Chromosomal 
Microarray (CMA) in Clinical Diagnostic
Zeeshan Ansar, Asghar Nasir, Nazneen Islam
Molecular Pathology 
Introduction 
The chromosomal microarray, also termed cytogenetic 
microarray, molecular karyotyping, or genomic copy 
number array, is a deoxyribonucleic acid (DNA)-based 
testing method used to identify copy-number variants 
(CNVs), which are either gains (i.e. duplications) 
or losses (i.e. deletions) of genomic material. This 
assay is a high resolution, whole-genome screening 
technique that can identify most of the chromosomal 
imbalances detected by conventional cytogenetic 
analysis, as well as smaller submicroscopic deletions 
and duplications that are referred to as copy-number 
variants (CNVs).Various human disorders may be 
caused by CNVs, including neurodevelopmental 
disorders and congenital anomalies such as cardiac 
defects. CMA is recommended as the first-tier test in 
the postnatal evaluation of congenital abnormalities 
and neurodevelopmental disorders as well as other 
constitutional or congenital diseases. 
CMA in particular is recommended when genetic 
analysis is performed in cases with clinical structural 
anomalies and/or karyotypical anomalies identified. 
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CMA should be considered as further evaluation 
when an apparently balanced de novo rearrangement 
is detected by karyotyping to exclude an imbalance at 
one or both of the translocation breakpoints. 
CMAs study is also proved to be  helpful tool in 
identifying the chromosomal origin and gene content 
of marker or ring chromosomes identified with 
conventional karyotype
Indications of CMA 
Chromosomal microarrays are recommended 
as a screening test by the American College of 
Medical Genetics when there is a family history of 
chromosomal abnormalities and there is a normal 
karyotype but suspected genetic conditions. 
Investigations could include; 1) identification of 
congenital genetic defects, 2) characterization 
of acquired genetic changes 3) determination of 
genomic variations and polymorphisms 4) individuals 
with multiple congenital anomalies, developmental 
delay/intellectual disability, and/or autism spectrum 
disorders, with clinically significant findings reported 
in approximately 15 percent of cases with normal 
conventional karyotypes
Therefore, CMA should be considered for clinical 
presentation of:
•	 Isolated autism spectrum disorder (ASD) or 
ASD plus other findings
•	 Isolated global developmental delay or 
intellectual disability
•	 Multiple congenital anomalies in the absence 
of a syndrome diagnosis
•	 Unusual physical features (dysmorphisms)
•	 Recurrent miscarriages
Limitations of CMAs
Limitations of the use of CMAs include: 
1. The inability to detect genetic events that 
do not affect the relative copy number of DNA 
sequences, for example., molecularly balanced 
chromosomal rearrangements. However, CMAs 
may reveal copy number changes in apparently 
“balanced” chromosomal rearrangements, i.e., 
gains or losses, at or near the chromosomal 
breakpoint sites.
2.  Low-level mosaicism for unbalanced 
chromosomal rearrangements and aneuploidy 
may not be detected by CMAs. The sensitivity of 
the microarray for detection of mosaicism will 
be influenced by the platform, sample type, copy 
number state, DNA quality, data quality, and 
size of imbalance.
3.  The chromosomal mechanism of a genetic 
imbalance may not be clarified. 
4.  Tetraploidy or other ploidy levels may not be 
 detected or may be difficult to detect.
5.  Genomic regions copy number variations   
 (CNVs) is not represented on the platform.
6.  Current CMA technologies are not designed  
 to detect duplications and deletions below 
the level of detection according to probe 
coverage and performance, point mutations, gene 
expression, and methylation anomalies that may 
contribute to the patient’s phenotype.
7.  No microarray platform will detect all 
mutations associated with a given syndrome. 
Therefore, failure to detect a copy number 
alteration at any locus does not exclude the 
diagnosis of a disorder associated with that 
locus.
Developmental delay (DD) and intellectual 
disability (ID) are estimated to affect ~ 1 percent 
of the children across the world. Genetic factors 
play a major part in DD/ ID (up to ~ 47.5 percent). 
Identification of  the genetic cause is crucial for 
accurate etiological diagnosis and refined clinical 
management. Chromosomal microarray analysis 
(CMA) has been recommended as a first-tier 
genetic test for unexplained DD/ID and congenital 
malformations. The reported diagnostic yields of 
clinical CMA vary between 12 and 20 percent, 
depending on the population and methods used.
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Constitutional/Congenital disease                                                                        
                                                                                       Significant Clinical finding on radiology/Other Labs 
 
                           CMA+ Karyotypes                                                              FISH/Karyotypes 
 
                                                                                                           
                                                                                                             Normal                        Abnormal  
 
                                                                                                                CMA 
 
  TSH Receptor Antibodies (TRAb) in Neonatal 
Hyperthyroidism: What We Need to Know?
Dr Zaib-un-Nisa
Clinical Chemistry
Neonatal hyperthyroidism, also known as neonatal 
Graves’ disease (NGD), is a rare disease occurs due to the 
Trans-placental passage of maternal stimulating TSH 
receptor antibodies (TRAb). It is mostly transient and 
permanent non-autoimmune neonatal hyperthyroidism 
is rare and is due to activating mutations of TSH receptor. 
Exposure to topical iodine has also been reported as 
a rare cause of hyperthyroidism in newborns. If it is 
not diagnosed early and treated correctly, can leads 
permanent intellectual disability in the baby. 
Graves’s hyperthyroidism occurs in approximately 
0.2 percent of women, and approximately one to five 
percent of infants born to these mothers developed 
NGD. TRAb are Immunoglobulin of G class and 
freely cross the placenta. Most NGD occurs in the 
setting of active or treated Graves’s hyperthyroidism 
in the mother. Thus, NGD would be expected to 
occur in approximately 1: 25,000 neonates and 
affects males and females equally.
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Any infant with unexplained 
tachycardia, goiter or stare, unexplained 
petechiae, hyperbilirubinemia, or 
hepatosplenomegaly, history of 
persistently high TRAb titer in mother 
during pregnancy, persistently high 
requirement for any thyroid medication 
in mother during pregnancy, thyroid 
ablation for hyperthyroidism in mother 
or previously affected sibling should 
be further investigated for NGD. The 
clinical manifestation of NGS are shown 
in Table 1.
For evaluation of any neonate suspected 
with the NGD, serum TRAb, TSH and 
FT4 testing is recommended. A low TSH, 
high FT4 along with TRAb levels higher 
than three-fold the upper limit of normal 
within 7 days of birth is predictive of the NGD. And 
if the TRAb levels are not detectable, the baby is very 
unlikely to become hyperthyroid. At Aga Khan Clinical 
Laboratories we are performing serum TRAb levels, 
using Chemiluminescence immunoassay..
Table 1: Clinical Spectrum of the NGD presenting in prenatal period and neonates.
Age Group Clinical Features
Prenatal Period (Fetus) •	 Unexplained tachycardia,
•	 Failure to thrive
•	 Intrauterine growth retardation
•	 Goiter




Neonate •	 Irritability, hyper excitability, sleep disorders
•	 Tachycardia, hypertension, cardiac failure
•	 Flushing, sweating, Goiter, stare
•	 Respiratory distress, pulmonary hypertension
•	 Increased appetite but no/poor weight gain
•	 Diarrhea
•	 Unexplained petechiae, hyperbilirubinemia
•	 Craniosynostosis, microcephaly,
•	 Death
An online  educational webinar series ‘Rare Links’ 
was initiated by Section of Chemical Pathology 
since December 2019, from the platform of Pakistan 
Inherited Metabolic Disease Network (Pak-IMD-Net), 
a working group of Pakistan society of Chemical 
Pathology. Aim of Rare links webinar series is to 
provide a platform where national and international 
experts can share their knowledge and experience 
of developed and developing newborn screening 
programs in and approaches to developing this in 
Pakistan. The webinar will feature presentations on the 
elements of a newborn screening program; talks on 
experiences and challenges of implementing newborn 
screening programs. Third webinar of this series was 
conducted via Zoom video conferencing on ‘Newborn 
Screening Program: An Impetus for change’ on 22nd 
September 2020. 
The focus of workshop was on understanding the 
basic concepts, components of a complete newborn 
screening program, and relate criteria for disorder 
selection to their individual circumstances. Webinar 
started with introduction of all participants followed 
by a talk by chair Pak-IMD-Net, Dr Lena Jafri. She 
briefed the participants about the aims and objectives 
of this working group and how Pak-IMD-Net is raising 
awareness about NBS. This was followed by lecture 
about ‘Laboratory Aspects of Newborn screening: 
What you need to know for establishing a NBS 
laboratory’ by Prof. Dr. Aamir Ijaz, co-chair, Pak-IMD-
Webinar ‘Newborn Screening Program: An 
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Net. This was followed by introduction to “rare links’ 
webinar series by Dr. Hafsa Majid. She shared the 
experience of establishing a successful NBS program 
at the Aga Khan University. Next was a talk given by 
Dr Aysha Habib Khan, Advisory council member for 
Society for Studies on inherited metabolic disorders, to 
further our understanding of the selecting the disorder 
to be include in NBS program established for Pakistani 
setup. She presented findings of the consensus report 
from the conference on ‘NBS in Pakistan’ conducted 
in 2019. 
The program concluded with panel discussion by 
national and international expert on ‘Developing 
Policy Recommendations for starting Nationwide 
NBS program in Pakistan’. The panelist included Dr 
Dianne Rosemary Webster, Director NBS program of 
New Zealand, Prof. Dr. Layachi Chabraoui, President 
Moroccan Society for Study of Inborn Errors of 
Metabolism, Dr. Khadija Humayun, Associate 
Professor and Consultant Pediatric Endocrinologist, 
Pediatric and Child Health, Aga Khan University, along 
with the presenters. 
It was a remarkably successful event, with more 
than 70 participants from 3 different countries, 
17 different cities, and 34 different institutes of 
Pakistan. The participants were from different 
areas of medicine including Pediatrics, Laboratory 
Medicine, Gynecology and Obstetrics, nursing, 
Family Medicine, Internal Medicine, and Public 
Health sectors. This was the third webinar of this 
series, and it was very well appreciated by all the 
participants. The participants encouraged organizers 
to conduct more such activities under the banner of 
‘Rare Links’.
The Best of the Past
Radiologist # Paediatricimaging # Followtheirlead  
Interviewee: Associate Prof Naila Nadeem 
Interview recorded by Dr. Shayan Anwar
1. Considering your entire time as paediatric 
imaging radiologist at your organization, can you 
recall a time (any AHAA moment) when you felt 
most alive or most excited about your involvement 
in the organization?
Prof Naila Nadeem: Every moment of my clinical 
experience in AKU has been worth narrating, however 
the most AHAA moments were when I worked 
with the multi-disciplinary team in management of 
“Conjoint Twins”, starting from imaging, then surgery 
and management was challenging. It is one of the best 
example of team work. I just could not stop my tears 
when I met the twins, separately held by parents, both 
healthy and happy.
2. Please briefly share your initial phase of 
journey i.e. from medical graduate to consultant.
Prof Naila Nadeem: Long journey, I have worked 
in four different government hospitals immediately 
after graduation, did 
my minor Diploma 
(MCPS) in radiology. 
The quest for better 
training made me 
apply in the residency 
program of AKU. I was 
fortunate to get selected 
as a resident in AKU in 
1997. I have no regrets 
to leave my consultant 
position in government 
job for a better training. My young and energetic 
batch mates kept me on my toes. Colleagues were 
supportive, respectful but challenged me every day.  
University is very supportive, I was encouraged 
to excel not only as a clinician but also as an 
educationist, I did MHPE which has further tested 
my endurance but is rewarding. I enjoy Pediatric 
radiology and medical education.
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The Best of the Past
Interview of the Professor of Pathology and Laboratory Medicine,
Interviewee: Professor Aysha Habib Khan 
Interview Recorded by Dr Syed Bilal Hashmi
1. Please share a brief journey/experience of 
establishing a Biochemical Genetics Laboratory?
Professor Aysha Habib Khan: I take pride in the 10 
years I have invested in realization of BGL and have a 
great sense of gratitude when I look back.  In 1995 after 
moving from pediatric residency to chemical pathology, 
I felt a major gap in the diagnostics of inborn errors of 
metabolism, this then became my passion to contribute 
towards this area of metabolic medicine. There was 
a genuine need of Biochemical Genetic Laboratory 
(BGL) for the community and healthcare. Establishing 
BGL was not an easy task and consumed 10 extensive 
years after my post-graduation.
Starting from advocacy down to planning and 
implementation and now, representing AKU and 
Pakistan in international forums are accomplishments 
that are difficult to 
describe and express. 
All I know is a strong 
foundation has been 
laid and now the entire 
BGL team including 
my technologists and 
faculty have got to give 
their best to reap fruits. 
Complete diagnostic 
setup will take its time 
but continuing in the 
right direction and developing & training younger lot 
to take it forward with updated knowledge and latest 
technique is the need for future.
  
2. What challenges did you face in establishing 
and leading the Biochemical genetics laboratory? 
3. Let’s consider for a moment the things you 
value deeply.  Specifically, the things you value 
about yourself and the nature of your work, what 
is the single most important thing your work has 
contributed to your life? 
Prof Naila Nadeem: Discipline, excellent work-place, 
lifelong learning desire all have contributed, but what 
has really affected me most is “altruism”. This is 
the splendor of AKU, it induces into us the “selfless 
concern for the well-being of our patients and for our 
colleagues”. 
4. As a senior Paediatric imaging radiologist 
of the country, please share your experience of 
development of paediatric imaging practices in 
Pakistan and its future in next 10 years. 
Prof Naila Nadeem: When I joined Pediatric imaging 
group, Dr. Yousuf was the only name, I am grateful 
to him for leading and building the team with open 
mind. Now Pediatric imaging is an established 
separate field in Pakistan. It is established in Karachi, 
Lahore, Multan and Islamabad. We now have our 
representation in radiology Society of Pakistan. At 
College of Physician Surgeons Pakistan (CPSP) level 
we are trying to establish fellowship programme. 
In next ten years I see further progress of pediatric 
radiology, as more and more dedicated centers for 
pediatric care are established. Still long way to go but 
we are very hopeful. 
5. Any advice for Junior Radiologists?
Prof Naila Nadeem: Be happy and gratified 
physicians, live up to your title “The Doctor”. Work 
with dedication for your patients. Role models like 
Dr. Gaffar Billoo teach us there is no age limit for 
learning and work hard. The smile on your patients’ 
face is the biggest reward, try to earn that.
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Furthermore, what were the success factors that 
helped you respond to these challenges?
Professor Aysha Habib Khan: As I said earlier, 
advocacy was the major challenge, which consumed 
significant time. Establishing a new specialty requires 
substantial resources, and with limited funds for entire 
hospital, it was not easy convincing decision makers 
to invest on something very new. New in a sense that 
biochemical genetic diagnostics specialty did not 
existed in Pakistan, with no data to prove that inherited 
metabolic disorders exist in sufficient numbers to be 
of public importance. The good part was that related 
clinical fraternity was cognizant of the missing facility 
and therefore, supported this endeavor voice fully.      
My perseverance and focused approach to achieve 
genetic lab objective was the main factor in overcoming 
the challenge. Despite of non-availability of funds, 
always enhancing my knowledge and remaining abreast 
of the happening and advancements taking place in the 
field further strengthening my zeal to equip the lab with 
genetic diagnostic facilities. 
3. Can you share any success story or “AHA 
Moment” where you felt very excited while making 
a diagnosis? 
Professor Aysha Habib Khan: The AHA moment to 
me was also the first milestone for us, in diagnosing 
the first case with inherited metabolic disease in 
“real time’. It so happened that before our services 
were operationalized; we were approached by Dr 
Bushra Afroze for a patient admitted in NICU for 
a clinical suspicion of a metabolic disorder and 
requested our support to determine the diagnosis. It 
was a weekend and on analysis it was identified to be 
a case of isovaleryl CO A dehydrogenase deficiency. 
Why I called it a milestone was with the reason 
that the lab team had before operationalizing got 
its first result tested, verified and communicated to 
the treating physician. Actual benefit was saving a 
precious neonate’s life, which otherwise would not 
have happened, unless the specimen was sent abroad 
for testing for verification. A heartening thank you 
note from Dr Bushra Afroze was not only a source 
of excitement for the team, but also a sense of 
accomplishment and a valuable contribution in the 
treatment of children, who were otherwise delayed 
for multiple reasons.
4. What contribution is the Biochemical genetics 
laboratory paying towards patient benefit? 
Professor Aysha Habib Khan: Now that the lab is 
formally accredited by college of American Pathologist; 
the most important and valuable contribution is access 
and prompt diagnosis from within AKU, thus saving a 
lot of time and providing financial relief to the family. 
The second important factor is close interaction and 
trust between treating physician and pathologist.
5. What are the plans or vision for the next ten 
years? 
Professor Aysha Habib Khan: We started small 
with just two equipments, but with a test menu that 
had maximum diagnostic yield. Now we are moving 
forward on optimizing and validating assays on HPLC 
and LCMSMS. With this, we will be able to expand our 
test menu and capture disorders that were not picked 
earlier. This would also provide opportunity to study 
the spectrum of diseases within Pakistan.
We have also laid down infrastructure and standard 
operating procedures for newborn screening program 
at AKUH. We started with screening for congenital 
hypothyroidism and now moving to screening for 
congenital adrenal hyperplasia. We hope to expand it 
for expanded newborn screening once the assays are 
validated.   
We have focused on human resource capacity building 
to oversee the specialty. These include eight faculty 
members including myself and 12 technologists. 
Intention is to train more faculty and technologist 
to ensure that gap does not not arise at any stage. 
Our faculty is now leading from front and we are 
collaborating with various international organizations 
including Mayo Laboratory in US and Society of Study 
of Inborn Errors of Metabolism (SSIEM).
At the same time, we have worked on developing 
the national capacity of physicians, pathologists and 
technologists across Pakistan through numerous 
conferences, continuing medical education, seminars, 
hands on workshops and other training ventures. 
Our intentions is to contribute nationally, developing 
human resource capacity to carryout diagnostics 
and interpretation of biochemical genetics data and 
facilitate families in all cities, regions and provinces 
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of Pakistan. This is how we would be able to serve 
community at large in line with Chancellor’s vision.
We hope to develop patient’s registries and support 
groups for raising awareness and education on genetic 
diseases for masses in future.
6. What advice will you give to the junior pathologist 
persuading career in the field of Biochemical 
genetics?
Professor Aysha Habib Khan: I would encourage 
participation from the seniors to nurture the juniors 
and for the juniors and newcomers to take on 
this field with zeal and enthusiasm. Biochemical 
genetics will now grow at a faster pace in Pakistan 
and youngsters wishing to pursue a career in this 
specialty will have a very bright future. To get into 
this field, one must have analytical approach and 
research aptitude. A strong foundation has been laid 
by AKUH. Developing & training younger lot to 
take it forward with updated knowledge and latest 
technique is the need for future. 
Histopathologists after conducting Pediatric Tumor Boards of multiple subspecialties
Polaroid
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Reporting of Flow Cytometry cases of Pediatric Hematological Malignancies  
Laboratory technical staff processing Paediatric Blood Culture bottle that was flagged positive in continuous blood culture 
monitoring system
Polaroid
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Positive Latex Particle Agglutination (LPA) test for Neisseria Meningitidis in Paediatric patient with suspected community 
acquired Meningitis
A Lab Scientist  performing Sweat Chloride testing to Screen for Cystic Fibrosis in a patient
Polaroid
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Polaroid
Faculty and Technologists of Chemical Pathology discussing the Chromatograms of Plasma Amino Acids and Urine 
Organic Acids in Departmental Consultation Conference
Paediatric Imaging Team Aga Khan University Hospital at Radiological Society of Pakistan: (left to right) - Dr Kiran Hilal, 
Dr Naila Nadeem, Dr Yousuf Husen, Dr Waseem Mirza and Dr Basit Salam
MAY 2021 VOL 46, ISSUE 3
36
Polaroid
Faculty, Laboratory technologist (Genetics bench) and Laboratory Manager at the section of Molecular Pathology, 
Clinical Laboratory, AKUH that are involved in pediatric molecular diagnostics
Computer analysis is used to compare a patient’s genetic material to that of a reference sample. 
A difference between a patient’s DNA and the reference sample is called a genetic variant.
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Polaroid
Haematology resident and blood bank staff performing and interpreting neonatal blood group by gel card method
Chief Guests at the Launch of Ek-Sath- an eportal for the support of patients and families with rare inherited metabolic 
defects (IMDs) in Pakistan
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